Drug intelligence / Profile preview

BR1018-1

Development stage: Phase 1
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

**BR1018-1** is an investigational Boryung drug product evaluated in a completed Phase 1 crossover study in healthy adults, both alone and in coadministration with BR1018-2. The study assessed pharmacokinetic interaction, safety, and tolerability in the context of hypertension and hyperlipidemia development. Public trial records do not disclose the precise active-ingredient composition, molecular target, dosage form, or mechanism specific to BR1018-1; it should not be conflated with the broader BR1018 hypertension and dyslipidemia development program.

Targets

NPC1L1 (Niemann-pick C1-Like 1 transporter)AGTR1 (Angiotensin II Type-1 receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on BR1018-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1018-1.

Explore the full profile